| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute liver failure in Budd–Chiari syndrome and a model to predict mortality
|
Thuluvath, Paul J.
|
|
|
15 |
1 |
p. 146-154
|
artikel
|
| 2 |
Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis
|
Lapidot, Y.
|
|
|
15 |
1 |
p. 191-201
|
artikel
|
| 3 |
Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates
|
Yang, Haiyan
|
|
|
15 |
1 |
p. 217-222
|
artikel
|
| 4 |
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
|
Yen, Fu-Shun
|
|
|
15 |
1 |
p. 179-190
|
artikel
|
| 5 |
Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB
|
Xu, Wei
|
|
|
15 |
1 |
p. 51-59
|
artikel
|
| 6 |
GATA6 modulates the ductular reaction to bile duct ligation
|
Pihlajoki, Marjut
|
|
|
15 |
1 |
p. 166-178
|
artikel
|
| 7 |
How can we reduce the impact of COVID-19 pandemic on timely access to liver transplantation in children?
|
Reddy, Mettu Srinivas
|
|
|
15 |
1 |
p. 215-216
|
artikel
|
| 8 |
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
|
Geng, Yana
|
|
|
15 |
1 |
p. 21-35
|
artikel
|
| 9 |
Implications of liver injury in risk-stratification and management of patients with COVID-19
|
Shao, Jiaofang
|
|
|
15 |
1 |
p. 202-212
|
artikel
|
| 10 |
Is it time to spit? More evidence for the oral–gut–liver axis in liver disease
|
Acharya, Chathur
|
|
|
15 |
1 |
p. 4-5
|
artikel
|
| 11 |
Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B
|
Hu, Gang
|
|
|
15 |
1 |
p. 60-70
|
artikel
|
| 12 |
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis
|
Zeng, Xin
|
|
|
15 |
1 |
p. 155-165
|
artikel
|
| 13 |
Management of primary sclerosing cholangitis and its complications: an algorithmic approach
|
Prokopič, Michal
|
|
|
15 |
1 |
p. 6-20
|
artikel
|
| 14 |
One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment
|
Tseng, Tai-Chung
|
|
|
15 |
1 |
p. 105-113
|
artikel
|
| 15 |
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis
|
Blanc, Jean-Frédéric
|
|
|
15 |
1 |
p. 93-104
|
artikel
|
| 16 |
Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy
|
Wu, Xiaoning
|
|
|
15 |
1 |
p. 82-92
|
artikel
|
| 17 |
Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study
|
Ma, Qiuyue
|
|
|
15 |
1 |
p. 127-136
|
artikel
|
| 18 |
Reductions in liver cirrhosis hospitalizations during the COVID-19 pandemic
|
Li, Jianglei
|
|
|
15 |
1 |
p. 213-214
|
artikel
|
| 19 |
Regression of portal hypertension: underlying mechanisms and therapeutic strategies
|
Selicean, Sonia
|
|
|
15 |
1 |
p. 36-50
|
artikel
|
| 20 |
Sequential combination therapies for HBeAg-positive chronic hepatitis B: the search continues
|
Jindal, Ankur
|
|
|
15 |
1 |
p. 1-3
|
artikel
|
| 21 |
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation
|
Lee, Soon Kyu
|
|
|
15 |
1 |
p. 137-145
|
artikel
|
| 22 |
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma
|
Qi, Lu-Nan
|
|
|
15 |
1 |
p. 114-126
|
artikel
|
| 23 |
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients
|
Liu, Matt
|
|
|
15 |
1 |
p. 71-81
|
artikel
|
Tijdschrift beschrijving